The direct answer: no exosome product is FDA approved
FDA has stated directly that there are no FDA-approved exosome products. That statement applies across the category. Any supplier or clinic describing an exosome product as FDA approved, cleared, or licensed is making a claim that does not match the agency's own public position.
This is a different regulatory situation than Wharton's jelly tissue products, and the difference matters for how clinics evaluate and document purchasing decisions.
Why exosomes are generally treated as section 351 biologic drugs, not 361 tissue products
Wharton's jelly allografts are generally offered under the HCT/P framework described in 21 CFR 1271.10, where a product can be regulated solely under section 361 of the Public Health Service Act without premarket approval if it meets specific criteria. Exosome and extracellular vesicle products are generally regulated differently, as biologic drugs under section 351, which is the pathway that requires an approved biologics license application.
That distinction is why exosome products do not have an analogous 1271.10 qualification question the way tissue allografts do. Purchase and clinical use decisions for these products belong to the physician, made with their own regulatory counsel, informed by this distinction rather than by marketing claims.
What FDA's consumer alerts say
FDA has issued public consumer alerts naming exosomes alongside stem cells as categories where unapproved products have reached the market, and separately has issued warnings about serious risks associated with unapproved regenerative medicine products generally. These are agency statements directed at the public, which is part of why the agency has treated public-facing marketing claims as a compliance priority.
For a buyer, the practical reading is that FDA's position is unambiguous and has been stated more than once: this category lacks approved products, and the agency is actively watching how it is marketed.
How characterization and terminology work for these products
Documentation helps identify a product; it does not confer authorization for clinical use. Review a product's status with regulatory counsel before relying on characterization data as anything more than a description of what is in the preparation. The 2023 Minimal Information for Studies of Extracellular Vesicles guidance, known as MISEV2023, recommends describing these preparations as extracellular vesicles unless exosome biogenesis has specifically been demonstrated, and recommends reporting source, size, concentration, and marker data consistently.
In practice, that means a buyer should expect to see characterization methods named explicitly, such as ELISA, nanoparticle tracking analysis, or single particle interferometric reflectance imaging sensing, along with identified marker proteins such as tetraspanins. These are analytical findings describing what is in a preparation, not statements about what the preparation does clinically.
What enforcement history signals for this category
FDA's 2026 warning letters to distributors of private-label exosome and Wharton's jelly products centered on disease-related claims made in marketing, not solely on manufacturing issues. The agency has stated it reads distributor and affiliate websites and social media as evidence of a product's intended use, and that a research-use-only label does not protect a product that is otherwise promoted for clinical use.
For exosome products specifically, because no approval pathway has been completed in this category at all, marketing language carries even more weight in how a product could be viewed by regulators. If applicable to your practice, review a supplier's public materials as part of due diligence, not only its paperwork.
What this means for purchasing and clinical decisions
None of this is a statement about whether a given exosome product has a place in a specific clinical workflow; that determination sits with the treating physician. FDA states there are no FDA-approved exosome products, these products are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions belong to the physician, made with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice. Questions about a specific product's regulatory status or a specific intended use should go to the clinic's own FDA regulatory counsel.
Frequently asked questions
Are any exosome products FDA approved?+
No. FDA has stated directly that there are no FDA-approved exosome products.
Why are exosomes regulated differently than Wharton's jelly tissue products?+
Exosome products are generally regulated as biologic drugs under section 351, which requires an approved biologics license application, rather than under the section 361 HCT/P framework that applies to some tissue allografts.
Does a 'research use only' label change the regulatory status of an exosome product?+
No. FDA has stated that a research-use-only label does not protect a product that is otherwise marketed or used clinically.
Who should make the decision to purchase or use an exosome product clinically?+
That decision belongs to the treating physician, made with their own regulatory counsel, informed by the product's documentation and characterization data rather than marketing claims.